|drug3736||anti-SARS-CoV-2 convalescent plasma Wiki||0.50|
There is one clinical trial.
The novel coronavirus (COVID-19) emerged in December 2019, and in mere months has spread to more than 104 countries, resulting in an outbreak of viral pneumonia worldwide. Current local quarantine policy in Hong Kong for individuals suspected for COVID-19 requires daily self-reported symptomatology and body temperature, given the intermittent nature and the high dependency of self-discipline undermine the practicality of the approach. To date, the advance in sensor technology has made possible to continuously monitor individual physiological parameters using a simple wearable device. Together with the mobile wearable technology that allowing instantaneous, multi-directional, and massive data transfer, remote continuous physiological monitoring is made possible. The Cardiology division, the Univeristy of Hong Kong has been in collaboration with Biofourmis to implement such technology for remote heart failure management. Similar digital therapeutic system can be applied to remotely monitor physiological parameters of large number of quarantined or suspected COVID-19 at home or in quarantine facility. It is purposed to allow the monitoring team to effectively and remotely monitor COVID-19 quarantined and patients, manage and evaluate the disease progression.
Description: Time from quarantine to diagnosis of COVID-19Measure: Time to diagnosis of COVID-19 by RT-PCR in subjects Time: within 14 days
Description: Adherence to deviceMeasure: Compliance to complete the study Time: within 14 days
Description: To identify COVID19 subjectsMeasure: Sensitivity and specificity of Biovitals® Sentinel Time: within 14 days
Description: % of family members infectionMeasure: Cross infection rate within the family cluster Time: within 14 days
Description: Length of hospital stayMeasure: Length of hospital stay of positive subjects Time: 1 year at study completion
Description: Length of ICU stayMeasure: Length of ICU stay of positive patients Time: 1 year at study completion
Description: Vital signs of positive patientsMeasure: National Early Warning Score 2 rating of positive patients Time: 4 weeks from diagnosis
Description: Virology laboratory result of nasopharyngeal swabMeasure: Viral load of positive patients Time: 4 weeks from diagnosis
Description: Worsening of comorbiditiesMeasure: Worsening of comorbidities Time: 1 year at study completion
Description: MortalityMeasure: Mortality Time: 1 year at study completion
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports